Ponezumab (PF-04360365, RN 1219) is a humanized anti-amyloid-beta (Amyloid-beta) IgG2 monoclonal antibody. Ponezumab reduces Abeta levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimers disease[1].
Molekulargewicht:
(145.65 kDa)
Reinheit:
97.89
CAS Nummer:
[1178862-65-1]
Target-Kategorie:
Amyloid-beta
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten